Mariangela Pierantozzi

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4553492/publications.pdf

Version: 2024-02-01

104 papers	4,515 citations	116194 36 h-index	124990 64 g-index
104 all docs	104 docs citations	104 times ranked	6709 citing authors

#	Article	IF	Citations
1	Adult-onset sporadic chorea: real-world data from a single-centre retrospective study. Neurological Sciences, 2022, 43, 387-392.	0.9	6
2	Biomarkers of Cerebral Glucose Metabolism and Neurodegeneration in Parkinsonâ€™s Disease: A Cerebrospinal Fluid-Based Study. Journal of Parkinson's Disease, 2022, 12, 537-544.	1.5	3
3	Neurotrophins as Therapeutic Agents for Parkinsonâ€™s Disease; New Chances From Focused Ultrasound?. Frontiers in Neuroscience, 2022, 16, 846681.	1.4	10
4	Effects of melatonin prolonged-release on both sleep and motor symptoms in Parkinsonâ€™s disease: a preliminary evidence. Neurological Sciences, 2022, 43, 5355-5362.	0.9	6
5	Not just a Snapshot: An Italian Longitudinal Evaluation of Stability of Gut Microbiota Findings in Parkinsonâ€™s Disease. Brain Sciences, 2022, 12, 739.	1.1	6
6	Depressive and anxiety symptoms in patients with SARS-CoV2 infection. Journal of Affective Disorders, 2021, 278, 339-340.	2.0	11
7	Deep brain stimulation in Parkinsonâ€™s disease patients and routine 6â€OHDA rodent models: Synergies and pitfalls. European Journal of Neuroscience, 2021, 53, 2322-2343.	1.2	5
8	Cognitive and Neuropsychiatric Profiles in Idiopathic Rapid Eye Movement Sleep Behavior Disorder and Parkinsonâ€™s Disease. Journal of Personalized Medicine, 2021, 11, 51.	1.1	9
9	Sleep problems affect quality of life in Parkinson's disease along disease progression. Sleep Medicine, 2021, 81, 307-311.	0.8	18
10	Frequency of Non-motor Symptoms in Parkinson's Patients With Motor Fluctuations. Frontiers in Neurology, 2021, 12, 678373.	1.1	14
11	Sudomotor and cardiovascular autonomic function in de novo Parkinson's disease assessed by sudoscan and cardiovascular reflexes. Journal of the Neurological Sciences, 2021, 427, 117502.	0.3	8
12	The Retinal Posterior Pole in Early Parkinsonâ€™s Disease: A Fundus Perimetry and SD-OCT Study. Clinical Ophthalmology, 2021, Volume 15, 4005-4014.	0.9	3
13	Systemic Activation of Nrf2 Pathway in Parkinson's Disease. Movement Disorders, 2020, 35, 180-184.	2.2	66
14	Clinical course of paroxysmal dyskinesias throughout pregnancy. Parkinsonism and Related Disorders, 2020, 80, 19-20.	1.1	5
15	Lateralization of cochlear dysfunction as a specific biomarker of Parkinsonâ€™s disease. Brain Communications, 2020, 2, fcaa144.	1.5	6
16	Physical Activity Changes and Correlate Effects in Patients with Parkinson's Disease during <scp>COVID</scp>â€19 Lockdown. Movement Disorders Clinical Practice, 2020, 7, 797-802.	0.8	53
17	Laterality of Auditory Dysfunction in Parkinson's Disease. Movement Disorders, 2020, 35, 1283-1284.	2.2	4
18	Dyspnea perception and neurological symptoms in non-severe COVID-19 patients. Neurological Sciences, 2020, 41, 2671-2674.	0.9	6

#	Article	IF	Citations
19	Self-reported needs of patients with Parkinsonâ€™s disease during COVID-19 emergency in Italy. Neurological Sciences, 2020, 41, 1373-1375.	0.9	59
20	Increased Noradrenaline as an Additional Cerebrospinal Fluid Biomarker in PSP-Like Parkinsonism. Frontiers in Aging Neuroscience, 2020, 12, 126.	1.7	5
21	Young-onset and late-onset Parkinson's disease exhibit a different profile of fluid biomarkers and clinical features. Neurobiology of Aging, 2020, 90, 119-124.	1.5	41
22	Pitolisant for treating narcolepsy comorbid with Parkinson's disease. Sleep Medicine, 2020, 69, 86-87.	0.8	4
23	Subjective neurological symptoms frequently occur in patients with SARS-CoV2 infection. Brain, Behavior, and Immunity, 2020, 88, 11-16.	2.0	159
24	Sleep and wake impairment in patients with SARS-CoV2 infection. Sleep Medicine, 2020, 73, 177-178.	0.8	0
25	Mechanisms of action underlying the efficacy of deep brain stimulation of the subthalamic nucleus in Parkinson's disease: central role of disease severity. European Journal of Neuroscience, 2019, 49, 805-816.	1.2	20
26	Dysbiosis of gut microbiota in a selected population of Parkinson's patients. Parkinsonism and Related Disorders, 2019, 65, 124-130.	1.1	144
27	Cerebral glucose metabolism in idiopathic REM sleep behavior disorder is different from tau-related and Î±-synuclein-related neurodegenerative disorders: A brain [18F]FDG PET study. Parkinsonism and Related Disorders, 2019, 64, 97-105.	1.1	22
28	Dietary Vitamin E as a Protective Factor for Parkinson's Disease: Clinical and Experimental Evidence. Frontiers in Neurology, 2019, 10, 148.	1.1	89
29	Alexithymia and anhedonia in early Richardson's syndrome and progressive supranuclear palsy with predominant parkinsonism. Brain and Behavior, 2019, 9, e01448.	1.0	9
30	Daytime sleepiness may be an independent symptom unrelated to sleep quality in Parkinsonâ€™s disease. Journal of Neurology, 2019, 266, 636-641.	1.8	28
31	Dopaminergic involvement in a drummer with focal dystonia: A case study. Clinical Neurology and Neurosurgery, 2018, 166, 54-55.	0.6	2
32	Effective treatment of restless legs syndrome by safinamide in Parkinson's disease patients. Sleep Medicine, 2018, 41, 113-114.	0.8	16
33	Anosognosia for cognitive and behavioral symptoms in Parkinson's disease with mild dementia and mild cognitive impairment: Frequency and neuropsychological/neuropsychiatric correlates. Parkinsonism and Related Disorders, 2018, 54, 62-67.	1.1	32
34	Restless legs syndrome is highly prevalent in patients with postpolio syndrome. Sleep Medicine, 2018, 41, 112.	0.8	0
35	Does fatigue in Parkinsonâ€™s disease correlate with autonomic nervous system dysfunction?. Neurological Sciences, 2018, 39, 2169-2174.	0.9	7
36	Psychiatric profile of motor subtypes of de novo drugâ€naÃ¯ve Parkinson's disease patients. Brain and Behavior, 2018, 8, e01094.	1.0	4

#	Article	IF	Citations
37	Safinamide effect on sleep disturbances and daytime sleepiness in motor fluctuating Parkinson's disease patients: A validated questionnaires-controlled study. Parkinsonism and Related Disorders, 2018, 57, 80-81.	1.1	25
38	When Cognitive Decline and Depression Coexist in the Elderly: CSF Biomarkers Analysis Can Differentiate Alzheimer's Disease from Late-Life Depression. Frontiers in Aging Neuroscience, 2018, 10, 38.	1.7	25
39	Quality of life in Parkinsonâ€™s disease: Italian validation of the Parkinsonâ€™s Disease Questionnaire (PDQ-39-IT). Neurological Sciences, 2018, 39, 1903-1909.	0.9	32
40	Continuous Positive Airway Pressure Treatment May Improve Optic Nerve Function in Obstructive Sleep Apnea: An Electrophysiological Study. Journal of Clinical Sleep Medicine, 2018, 14, 953-958.	1.4	12
41	Homovanillic acid in CSF of mild stage Parkinson's disease patients correlates with motor impairment. Neurochemistry International, 2017, 105, 58-63.	1.9	33
42	Which patients discontinue? Issues on Levodopa/carbidopa intestinal gel treatment: Italian multicentre survey of 905 patients with long-term follow-up. Parkinsonism and Related Disorders, 2017, 38, 90-92.	1.1	44
43	Neuropsychiatric and cognitive profile of early Richardson's syndrome, Progressive Supranuclear Palsy-parkinsonism and Parkinson's disease. Parkinsonism and Related Disorders, 2017, 45, 50-56.	1.1	31
44	Cerebrospinal-fluid Alzheimerâ€™s Disease Biomarkers and Blood-Brain Barrier Integrity in a Natural Population of Cognitive Intact Parkinsonâ€™s Disease Patients. CNS and Neurological Disorders - Drug Targets, 2017, 16, 339-345.	0.8	12
45	Cerebrospinal fluid lactate levels and brain [18F]FDG PET hypometabolism within the default mode network in Alzheimerâ€™s disease. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 2040-2049.	3.3	73
46	Optic Nerve Dysfunction in Obstructive Sleep Apnea: An Electrophysiological Study. Sleep, 2016, 39, 19-23.	0.6	26
47	Rotigotine may improve sleep architecture in Parkinson's disease: a double-blind, randomized, placebo-controlled polysomnographic study. Sleep Medicine, 2016, 21, 140-144.	0.8	55
48	Involvement of Subcortical Brain Structures During Olfactory Stimulation in Multiple Chemical Sensitivity. Brain Topography, 2016, 29, 243-252.	0.8	31
49	Rotigotine effect on sleep in a de novo Parkinson's Disease patient affected by periodic limb movement disorder. Parkinsonism and Related Disorders, 2015, 21, 1476-1478.	1.1	4
50	Autonomic Function Tests and <scp>MIBG</scp> in Parkinson's Disease: Correlation to Disease Duration and Motor Symptoms. CNS Neuroscience and Therapeutics, 2015, 21, 727-732.	1.9	23
51	Catecholamine-Based Treatment in AD Patients: Expectations and Delusions. Frontiers in Aging Neuroscience, 2015, 7, 67.	1.7	21
52	Commentary: Clinical Correlates of Raphe Serotonergic Dysfunction in Early Parkinsonâ€™s Disease. Frontiers in Neurology, 2015, 6, 261.	1.1	2
53	Restless Legs Syndrome and Poliomyelitis: New Evidences of an Old Observation?. Frontiers in Neurology, 2015, 6, 23.	1.1	6
54	Unraveling predictors affecting compliance to MRI inÂParkinson'sÂdisease. Parkinsonism and Related Disorders, 2015, 21, 964-967.	1.1	2

#	Article	IF	Citations
55	Efficacy and safety profile of prolonged release oxycodone in combination with naloxone (OXN PR) in Parkinsonâ€™s disease patients with chronic pain. Journal of Neurology, 2015, 262, 2164-2170.	1.8	35
56	Serotonin Impairment in CSF of PD Patients, without an Apparent Clinical Counterpart. PLoS ONE, 2014, 9, e101763.	1.1	26
57	The early course of affective and cognitive symptoms in de novo patients with Parkinsonâ€™s disease. Journal of Neurology, 2014, 261, 1126-1132.	1.8	14
58	Transient parkinsonism after unilateral midbrain stroke: a compensatory intervention from the healthy side?. Neurological Sciences, 2014, 35, 2013-2015.	0.9	6
59	Epsteinâ€“Barr virus neuraxis infection as a trigger for central nervous system demyelinating processes: a case report. Multiple Sclerosis Journal, 2013, 19, 380-381.	1.4	3
60	HEDONIC TONE AND ITS MOOD AND COGNITIVE CORRELATES IN PARKINSON'S DISEASE. Depression and Anxiety, 2013, 30, 85-91.	2.0	11
61	Does 123I-MIBG scintigraphy really assist the diagnosis of Parkinson's disease?. Parkinsonism and Related Disorders, 2013, 19, 772-773.	1.1	10
62	The Serendipity Case of the Pedunculopontine Nucleus Low-Frequency Brain Stimulation: Chasing a Gait Response, Finding Sleep, and Cognition Improvement. Frontiers in Neurology, 2013, 4, 68.	1.1	40
63	Cardiac sympathetic denervation is not related to nigrostriatal degeneration in Parkinsonâ€™s disease. Annals of Nuclear Medicine, 2013, 27, 444-451.	1.2	27
64	Successful subthalamic stimulation, but levodopa-induced dystonia, in a genetic Parkinsonâ€™s disease. Neurological Sciences, 2013, 34, 383-386.	0.9	10
65	Depressive symptoms in Parkinson’s disease and in non-neurological medical illnesses. Neuropsychiatric Disease and Treatment, 2013, 9, 389.	1.0	8
66	Blood Dendritic Cell Frequency Declines in Idiopathic Parkinsonâ€™s Disease and Is Associated with Motor Symptom Severity. PLoS ONE, 2013, 8, e65352.	1.1	38
67	Strength and Weaknesses of Cerebrospinal Fluid Biomarkers in Alzheimer’s Disease and Possible Detection of Overlaps with Frailty Process. CNS and Neurological Disorders - Drug Targets, 2013, 12, 538-546.	0.8	5
68	Deep Brain Stimulation of Pedunculopontine Tegmental Nucleus: Role in Sleep Modulation in Advanced Parkinson Disease Patientsâ€”One-Year Follow-Up. Sleep, 2012, 35, 1637-1642.	0.6	54
69	Sad and happy facial emotion recognition impairment in progressive supranuclear palsy in comparison with Parkinson's disease. Parkinsonism and Related Disorders, 2012, 18, 871-875.	1.1	23
70	Increased blood-cerebrospinal fluid transfer of albumin in advanced Parkinsonâ€™s disease. Journal of Neuroinflammation, 2012, 9, 188.	3.1	115
71	The Impact of Rotigotine on Cardiovascular Autonomic Function in Early ParkinsonÂ’s Disease. European Neurology, 2012, 68, 187-192.	0.6	15
72	A non-comparative assessment of tolerability and efficacy of duloxetine in the treatment of depressed patients with Parkinson's disease. Expert Opinion on Pharmacotherapy, 2012, 13, 2269-2280.	0.9	25

#	Article	IF	Citations
73	Alexithymia Is a Non-Motor Symptom of Parkinson Disease. American Journal of Geriatric Psychiatry, 2012, 20, 133-141.	0.6	38
74	CSF and clinical hallmarks of subcortical dementias: focus on DLB and PDD. Journal of Neural Transmission, 2012, 119, 861-875.	1.4	16
75	Reduced GABA Content in the Motor Thalamus during Effective Deep Brain Stimulation of the Subthalamic Nucleus. Frontiers in Systems Neuroscience, 2011, 5, 17.	1.2	29
76	Intensity-dependent facial emotion recognition and cognitive functions in Parkinsonâ€™s disease. Journal of the International Neuropsychological Society, 2010, 16, 867-876.	1.2	49
77	Therapy for dyskinesias in Parkinsonâ€™s disease patients. Future Neurology, 2010, 5, 277-299.	0.9	1
78	Non-motor functions in parkinsonian patients implanted in the pedunculopontine nucleus: Focus on sleep and cognitive domains. Journal of the Neurological Sciences, 2010, 289, 44-48.	0.3	99
79	Magnetic resonance imaging markers of Parkinsonâ€™s disease nigrostriatal signature. Brain, 2010, 133, 3423-3433.	3.7	374
80	Effects of deep brain stimulation of the peduncolopontine area on working memory tasks in patients with Parkinson's disease. Parkinsonism and Related Disorders, 2010, 16, 64-67.	1.1	53
81	Multi-target strategy for Parkinsonian patients: The role of deep brain stimulation in the centromedianâ€“parafascicularis complex. Brain Research Bulletin, 2009, 78, 113-118.	1.4	89
82	Correlation between changes in CSF dopamine turnover and development of dyskinesia in Parkinson's disease. Parkinsonism and Related Disorders, 2009, 15, 383-389.	1.1	46
83	Grammar improvement following deep brain stimulation of the subthalamic and the pedunculopontine nuclei in advanced Parkinson's disease: A pilot study. Parkinsonism and Related Disorders, 2009, 15, 606-609.	1.1	41
84	CSF biomarkers, impairment of cerebral hemodynamics and degree of cognitive decline in Alzheimer's and mixed dementia. Journal of the Neurological Sciences, 2009, 283, 109-115.	0.3	66
85	Motor and Non-motor Effects of PPN-DBS in PD Patients: Insights from Intra-operative Electrophysiology. Advances in Behavioral Biology, 2009, , 573-587.	0.2	4
86	Pedunculopontine nucleus deep brain stimulation changes spinal cord excitability in Parkinsonâ€™s disease patients. Journal of Neural Transmission, 2008, 115, 731-735.	1.4	59
87	l-dopa modulates motor cortex excitability in Alzheimerâ€™s disease patients. Journal of Neural Transmission, 2008, 115, 1313-1319.	1.4	43
88	Sleep-wake cycle and effects of cabergoline monotherapy in de novo Parkinsonâ€™s disease patients. Journal of Neurology, 2008, 255, 1032-1037.	1.8	19
89	Bilateral deep brain stimulation of the pedunculopontine and subthalamic nuclei in severe Parkinson's disease. Brain, 2007, 130, 1596-1607.	3.7	739
90	CSF markers in Alzheimer disease patients are not related to the different degree of cognitive impairment. Journal of the Neurological Sciences, 2006, 251, 124-128.	0.3	52

#	Article	IF	Citations
91	123I-FP-CIT in progressive supranuclear palsy and in ParkinsonÊ¼s disease: a SPECT semiquantitative study. Nuclear Medicine Communications, 2006, 27, 381-386.	0.5	43
92	Biochemical and electrophysiological changes of substantia nigra pars reticulata driven by subthalamic stimulation in patients with Parkinson's disease. European Journal of Neuroscience, 2006, 23, 2923-2928.	1.2	114
93	Spontaneous sleep modulates the firing pattern of Parkinsonian subthalamic nucleus. Experimental Brain Research, 2006, 168, 277-280.	0.7	24
94	123I-FP-CIT semi-quantitative SPECT detects preclinical bilateral dopaminergic deficit in early ParkinsonÊ¼s disease with unilateral symptoms. Nuclear Medicine Communications, 2005, 26, 421-426.	0.5	77
95	Subthalamic stimulation activates internal pallidus: Evidence from cGMP microdialysis in PD patients. Annals of Neurology, 2005, 57, 448-452.	2.8	122
96	High endogenous cannabinoid levels in the cerebrospinal fluid of untreated Parkinson's disease patients. Annals of Neurology, 2005, 57, 777-779.	2.8	150
97	The effect of levodopa therapy on dopamine transporter SPECT imaging with 123I-FP-CIT in patients with Parkinsonâ€™s disease. European Journal of Nuclear Medicine and Molecular Imaging, 2005, 32, 1452-1456.	3.3	58
98	AD with subcortical white matter lesions and vascular dementia: CSF markers for differential diagnosis. Journal of the Neurological Sciences, 2005, 237, 83-88.	0.3	55
99	Stimulation of the subthalamic nucleus compared with the globus pallidus internus in patients with Parkinson disease. Journal of Neurosurgery, 2004, 101, 195-200.	0.9	89
100	Effect of Vigabatrin on motor responses to transcranial magnetic stimulation. Brain Research, 2004, 1028, 1-8.	1.1	51
101	Dbs in Parkinsonian Subthalamic Nucleus: Electrophysiological and Biochemical Changes. Advances in Behavioral Biology, 2002, , 3-12.	0.2	0
102	Microdialysis in Parkinsonian Patient Basal Ganglia: Acute Apomorphine-Induced Clinical and Electrophysiological Effects Not Paralleled by Changes in the Release of Neuroactive Amino Acids. Experimental Neurology, 2001, 167, 356-365.	2.0	42
103	Helicobacter pylori-induced reduction of acute levodopa absorption in parkinson's disease patients. Annals of Neurology, 2001, 50, 686-687.	2.8	47
104	An electrophysiological study of D2 dopaminergic actions in normal human retina: A tool in Parkinson's disease. Neuroscience Letters, 1992, 140, 125-128.	1.0	24